Xynos Konstantinos, the Chief Medical Officer at Replimune Group, Inc., has reported a transaction involving the sale of 16,198 shares of the company's common stock. This sale was executed to cover tax withholding obligations associated with the vesting of his restricted stock units (RSUs). Such transactions are common in the biotechnology sector, where stock-based compensation is prevalent.
The filing, dated November 18, 2026, indicates that the shares were sold at a weighted average price of $21.60, with prices ranging from $21.58 to $21.60 per share. This sale does not represent a discretionary action by Konstantinos, but rather a necessary step to meet tax obligations. The filing states, "The transaction reported herein was made in accordance with the irrevocable 'sell to cover' provision set forth in the award agreements under which the RSUs were granted."
Replimune Group, Inc. operates within the biological products industry, specifically focusing on the development of innovative therapies. The company is listed under the Central Index Key (CIK) 0001737953. The recent filing by Konstantinos highlights the ongoing practices of executive compensation in the biotechnology field, which often includes stock options and RSUs as part of their remuneration packages.
Following this transaction, Konstantinos retains ownership of 208,017 shares of Replimune Group's common stock. The sale may impact how stakeholders view executive compensation and the financial practices within the biotech industry.
Details regarding any future filings or actions were not disclosed in the SEC filing.
Read Next
Replimune's Schwendenman Sells Shares to Cover Tax Obligations
Martin David Norman sells 4,800 shares of Guardian Pharmacy
Chen Zhiwu Acquires Additional Shares in GigaCloud Technology
Kenneth E. Lebensburger Jr. Acquires Additional Shares in GigaCloud
Radakovich Lynn Vojvodich Reports Stock Transactions for Figma
Ferring Russell Shea acquires 2,588 RSUs at Firefly Aerospace









